Breast Cancer

The optimal risk-to-benefit dosage of sacituzumab govitecan-hziy is 10 mg/kg, calculated from dose-escalation and dose-expansion studies.

Antibody–drug conjugates are at the leading edge of innovation and efficacy in breast cancer treatment. Research efforts continue in order to establish further novel targets and thus further advance patient outcomes.

1 oncologist
1 bilingual nurse coordinator
1 social worker
1 community cancer care navigator
Here’s how they improved care for 101 underserved women with breast cancer.

Telemedicine may play a critical role by creating pathways for overcoming obstacles to healthcare access, particularly for breast cancer reconstruction.

Analysis from the PALOMA-3 clinical trial showed that the combination of palbociclib and fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Thrombotic event incidence was higher in this real-world study than that which was reported in clinical trials, with arterial thrombosis accounting for more than one-third of events.

Results of this real-world study demonstrated that the impact of abemaciclib complements the pivotal clinical trial data.

Primary analysis of a multicenter, randomized clinical trial suggests that endocrine therapy demonstrates benefits over capecitabine when used as a maintenance therapy after first-line combination chemotherapy in hormone receptor–positive, HER2-negative advanced metastatic breast cancer.

This real-world study of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with a palbociclib-based therapy as either first- or second-line therapy, showed similar safety and efficacy when compared with clinical study results.

During the COVID-19 pandemic, there was a decline in the number of patients beginning first-line treatment. There was a decrease in the percentage of patients receiving CDK4/6 inhibitor combination therapy while a simultaneous increase in endocrine monotherapy was observed.